louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00596388: Usage of the Home Macular Perimeter (HMP)
Official title: Usage of the Home Macular Perimeter (HMP) in Intermediate Age Related Macular Degeneration Patients Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Age Related Macular Degeneration
Keywords: HMP, AMD, CNV, PHP, HPHP
Lead sponsor: Notal Vision Inc.
Sponsor class: INDUSTRY
First posted: 2008-01-17
Enrollment: 20
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: • Subjects diagnosed as intermediate AMD

Brief summary: Demonstrate the ability of the current interactive tutorial and 1-800 support to teach an AMD patient to use the HMP device.

Detailed description: The pilot study purpose is to demonstrate that the tutorial which is part of the device software, is giving sufficient training for the intended users.

Eligibility criteria: Inclusion Criteria:

* Capable and willing to sign a consent form and participate in the study
* Subjects diagnosed as intermediate AMD in at least one eye
* Age \>50 years
* VA with habitual correction \>20/60 in the study eye
* Ability to speak, read and understand instructions in Hebrew
* Familiar with computer usage

Exclusion Criteria:

* Evidence of macular disease other than AMD or glaucoma in the study eye
* Presence of any significant media opacity that precludes a clear view of the macular area as identified in the study eye by biomicroscopy, CFP.
* Any non-macular related ocular surgery performed within 3 months prior to study entry in the target eye
* Participation in another study with the exclusion of AREDS study
* Patients diagnosed with geographic atrophy (GA)

Primary outcomes:
measure: Proportion of subjects who manage to use the device as in a daily testing
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Afula
country: Israel
facility: Haemek Medical center
Study officials:
affiliation: Haemek Hospital
name: Yaron Mr Lang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01672788: Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets
Official title: Bioequivalence of Empagliflozin/Metformin (850 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open-label, Randomised, Single-dose, Four-way Crossover Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2012-08-27
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The primary objective of this trial is to establish bioequivalence of two FDC tablets and the single tablets when administered together after a high fat high caloric meal.


Eligibility criteria: Inclusion criteria:

1. Healthy male and female subjects

Exclusion criteria:

1. Any relevant deviation from healthy conditions

Primary outcomes:
measure: Empa: Area Under the Curve 0 to Infinity (AUC0-∞)
timeFrame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
measure: Metformin: Area Under the Curve 0 to Infinity (AUC0-∞)
timeFrame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
measure: Empa: Maximum Measured Concentration (Cmax)
timeFrame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
measure: Metformin: Maximum Measured Concentration (Cmax)
timeFrame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Secondary outcomes:
measure: Empa: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)
timeFrame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
measure: Metformin: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)
timeFrame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Other outcomes:
Locations:
city: Biberach
country: Germany
facility: 1276.7.1 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
Clinical trial NCT01066988: Evaluation of an Investigational Lubricant Eye Drop on Lipid Layer Thickness
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dry Eye
Keywords: lipid layer thickness
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2010-02-11
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effects of an investigational lubricant eye drop on tear film lipid layer thickness of dry eye patients.


Eligibility criteria: Inclusion Criteria:

* Patients (minimum age 18) meeting specific criteria for dry eye.

Exclusion Criteria:

* Use of topical ocular drops within 12 hours of the study visit; or use of topical ocular ointment within 36 hours of the study visit. In addition, cannot use any topical ocular drugs during study period.
* History or evidence of ocular or systemic medical conditions and/or medications that would confound the evaluation.

Primary outcomes:
measure: Lipid layer thickness
timeFrame: Baseline through 120 minutes post instillation
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Alcon Call Center for Trial Locations
state: Texas
Study officials:
References:
citation: Benelli U. Systane lubricant eye drops in the management of ocular dryness. Clin Ophthalmol. 2011;5:783-90. doi: 10.2147/OPTH.S13773. Epub 2011 Jun 10.
Clinical trial NCT01170988: Coronary Flow Rate Measurement in T-Grafts
Official title: Comparison of Coronary Flow Reserve in Two Different Bypass Techniques (T-graft Technique Versus Isolated Graft Technique) Using Magnetic Resonance Technology (MRT)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Coronary Heart Disease
Keywords: patients scheduled for bypass grafting
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
Collaborators: name: Bethanien Krankenhaus gGmbH
First posted: 2010-07-28
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Is the surgical treatment of patients with coronary heart disease using the T-graft technique an adequate solution that provides a sufficient myocardial flow reserve? A magnetic resonance examination (MRI) is required.


Eligibility criteria: Inclusion Criteria:

* coronary heart disease
* Age \> 18 ys
* Ejection fraction \> 45%

Exclusion Criteria:

* myocardial infarction
* Re-Intervention

Primary outcomes:
measure: Coronary flow reserve
timeFrame: within 4-6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Frankfurt am Main
country: Germany
facility: Johann Wolfgang Goethe Universitätsklinikum
Study officials:
References:
Clinical trial NCT00239278: Budesonide / Formoterol in Treatment of Exacerbations of COPD
Official title: Effects of High Dose Inhaled Budesonide+ Formoterol Versus Placebo and Oral Prednisolone on Biomarkers of Airway Inflammation in the Treatment of Exacerbations in Non-hospitalised Patients With Mild to Moderate COPD.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Obstructive Pulmonary Disease
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2005-10-17
Enrollment: 120
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the budesonide+formoterol combination is effective in the treatment of exacerbations of COPD with a main emphasis on investigating the effects on inflammation and a secondary emphasis on clinical efficacy


Eligibility criteria: Inclusion Criteria:

* smoking-induced COPD according to ATS criteria
* FEV1 \<85% of predicted at enrolment and \<70% of predicted but \> 0.7 Liter at Exacerbation
* FEV1/IVC ratio \<88% of predicted for men and \<89% for women

Exclusion Criteria:

* history of asthma
* known hypersensitivity to the study drugs
* serious concomitant diseases
* pregnancy or lactating
* abnormal Chest X-ray or blood gasses

Primary outcomes:
measure: Eosinophils in induced sputum (as % of Total Cell Count), change from the start of the exacerbation to the end of 14 days treatment
Secondary outcomes:
measure: Inflammatory markers in induced sputum, blood/serum and urine
measure: Lung function tests at clinic
measure: Diary cards for PEF and symptoms
measure: Patient Related outcomes
measure: Questioning for Adverse Events and in blood: routine tests and cortisol
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: Research Site
Study officials:
affiliation: AstraZeneca
name: AstraZeneca Netherlands Medical Director, MD
role: STUDY_DIRECTOR
References:
citation: Bathoorn E, Liesker JJ, Postma DS, Boorsma M, Bondesson E, Koeter GH, Kauffman HF, van Oosterhout AJ, Kerstjens HA. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations. COPD. 2008 Oct;5(5):282-90. doi: 10.1080/15412550802363360.
citation: Bathoorn E, Liesker J, Postma D, Koeter G, van Oosterhout AJ, Kerstjens HA. Safety of sputum induction during exacerbations of COPD. Chest. 2007 Feb;131(2):432-8. doi: 10.1378/chest.06-2216.
Clinical trial NCT02120378: Fetal Viability Estimation in Egypt
Official title: Correlation Between Fetal Gestational Age, Viability and Survival Rates in Egypt
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Premature Birth
Miscarriage
Keywords: miscarriage
fetal viability
prematurity
Lead sponsor: Woman's Health University Hospital, Egypt
Sponsor class: OTHER
First posted: 2014-04-22
Enrollment: 1000
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: females presenting to the causality department in kasr el Aini hospital presenting with signs of preterm labor ( uterine contractions before completing 38 weeks of gestation)

Brief summary: Due to the discrepancy between the Egyptian and the conventional definition of miscarriage or live birth, there seemed to be a need for a study that ends up with reaching a definition for the mentioned terms. live birth is known to be for fetus born after 20 weeks or of weight more than 500 grams, while in Egypt, this is not applicable. basically the neonate has a chance of survival if the weight is more than 1000 grams or of gestational age more than 26 weeks.


Eligibility criteria: Inclusion Criteria:

* pregnant females age from 18- 40 years old
* preterm delivery before completing 38 weeks of gestation
* singleton or multiple gestation
* fetuses with congenital anomalies

Exclusion Criteria:

* refusal to get enrolled in the study

Primary outcomes:
measure: determination of age of fetal viability according the survival rate percentage
timeFrame: 1 year
Secondary outcomes:
measure: most common causes for premature delivery in Egypt
timeFrame: 6 months
measure: the mode of delivery of preterm cases in Egypt
timeFrame: 10 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr El Aini
Study officials:
affiliation: Cairo University
name: dina m dakhly, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00062478: Study of Karenitecin (BNP1350) in Patients With Brain Tumors
Official title: Phase 2 Treatment of Adults With Primary Malignant Glioma With Karenitecin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Brain Neoplasms
Malignant Neoplasms, Brain
Brain Tumors
Lead sponsor: BioNumerik Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Crown Bioscience
First posted: 2003-06-12
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.


Eligibility criteria: * Confirmed diagnosis of a newly diagnosed glioblastoma multiforme or recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or anaplastic oligodendroglioma.
* Evidence of measurable recurrent or residual primary CNS neoplasm.
* An interval of at least 3 weeks between prior surgical resection or 6 weeks between prior radiotherapy or chemotherapy, and enrollment on this protocol unless there is unequivocal evidence of tumor progression after surgery, radiotherapy, or chemotherapy.
* Hematocrit \> 29%, ANC \> 1,500, platelets \> 125,000
* Serum creatinine \< 1.5 mg/dl, BUN \< 25 mg/dl, serum SGOT and bilirubin \< 1.5 times upper limit of normal
* Negative pregnancy test for female patients

Primary outcomes:
measure: Objective Tumor Response Rate
timeFrame: Randomization to end of treatment
Secondary outcomes:
measure: Overall Survival
timeFrame: Randomization to date of death due to any cause
measure: Overall Safety
timeFrame: Randomization to end of study participation
Other outcomes:
Locations:
city: Durham
country: United States
facility: For Information call 210-614-1701 for a site near you
state: North Carolina
Study officials:
References:
Clinical trial NCT05079178: Newborns in Level III Services in Alsace From Mothers With COVID-19
Official title: Retrospective Clinical Study of the Care and Follow-up in the First Month of Life of Newborns in Level III Services in Alsace From Mothers With COVID-19
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Keywords: COVID-19
SARS-COV-2
Newborns of COVID-19 mothers
COVID-19 Pandemic
COVID-19 Virus Disease
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2021-10-15
Enrollment: 50
Sex: ALL
Minimum age (years): 1
Maximum age (years): 1
Standard ages: CHILD
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Newborns born between March 1 and June 30, 2020 to COVID 19 from positive mothers in Strasbourg University Hospital or Mulhouse Hospital.

Brief summary: Very little is known about the impact on the newborn of late pre-partum maternal SARS-CoV-2 infection.

Care without separation of the mother and her newborn with continued breastfeeding has been advocated in France and by the WHO but is being debated in some countries.

Assessment of the development of newborns in their first month of life with this strategy associated with close and secure follow-up.

Importance of reporting the potential benefits / risks of this treatment to guide the care of newborns in a persistent epidemic context in a particularly affected region.


Eligibility criteria: Inclusion criteria:

* Newborns born between March 1 and June 30, 2020 to COVID 19
* From positive mothers in Strasbourg University Hospital or Mulhouse Hospital.
* Parents' non-opposition to the analysis of hospitalization data for children contained in the medical file

Exclusion criteria:

- Parents' opposition to the analysis of hospitalization data for children contained in the medical file

Primary outcomes:
measure: Retrospective description of the care and follow-up in the first month of life of newborns in level III services in Alsace from mothers with COVID-19
timeFrame: Files analysed retrospectively from March 01, 2020 to Jun 30, 2020 will be examined]
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Médecine et Réanimation du Nouveau-né - Hôpitaux Universitaires de Strasbourg
Study officials:
References:
Clinical trial NCT01527578: Simons Variation in Individuals Project, Functional Common Acquisition Protocol
Official title: Functional Common Acquisition Protocol Phase of the Simons VIP
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: Healthy children
Healthy adults
individuals ages 7-60
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: Children's Hospital of Philadelphia
First posted: 2012-02-07
Enrollment: 120
Sex: ALL
Minimum age (years): 7
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy individuals ages 7 through 60.

Brief summary: The University of California, San Francisco (UCSF) Simons Variation in Individuals Project (Simons VIP) is currently recruiting healthy controls for a study aimed at better understanding autism spectrum disorder. The UCSF site of the Simons VIP is conducting functional and structural imaging, neuropsychological evaluation, genetic testing, and neurologic exams in healthy individuals to compare with findings in autism spectrum disorder.

Detailed description: To better understand autism spectrum disorders, the UCSF Simons VIP team is recruiting healthy controls to participate in a study involving brain imaging and psychological assessments and questionnaires. The study will involve phone interviews, cognitive testing and questionnaires, genetic testing, physical exam, photographs, non-invasive brain imaging sessions (MRI and MEG). The study can take up to 17 hours to complete, and there may be up to 5 study visits to UCSF and UC Berkeley.

Eligibility criteria: Inclusion Criteria:

* Healthy persons age 7 and older
* Must use English as primary language
* Must be able to lie still in MRI scanner for two hours
* Must be willing to travel to UCSF and UC Berkeley for up to 5 study visits.

Exclusion Criteria:

* Any metal implanted in the body
* Extensive dental work
* History of psychiatric of neurological illness
* History of drug or alcohol abuse

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California, San Francisco
state: California
Study officials:
affiliation: University of California, San Francisco
name: Elliott Sherr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04358978: A Novel Approach to Posterior Mesh Fixation in Laparoscopic Sacral Colpopexy
Official title: A Novel Approach to Posterior Mesh Fixation in Laparoscopic Sacral Colpopexy: a Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pelvic Organ Prolapse
Lead sponsor: Catholic University of the Sacred Heart
Sponsor class: OTHER
Collaborators: name: Miulli General Hospital
First posted: 2020-04-24
Enrollment: 150
Sex: FEMALE
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized controlled study is designed to test the non inferiority of no attachment of posterior mesh compared to fixation of posterior mesh to the vagina in laparoscopic sacral colpopexy in terms of anatomical correction of the prolapse, post-operative and long term morbidity and rate of recurrence.


Eligibility criteria: Inclusion Criteria:

-patients who required surgical treatment for symptomatic pelvic organ prolapse stage ≥ 2 with or without stress urinary incontinence

Exclusion Criteria:

* Age \> 75 years
* Severe cardiovascular or respiratory disease
* Pregnancy

Primary outcomes:
measure: correction of pelvic organ prolapse
timeFrame: 1 year
Secondary outcomes:
measure: rate of recurrence
timeFrame: 1 year
measure: long term outcomes
timeFrame: 1 year
Other outcomes:
Locations:
city: Acquaviva delle Fonti
country: Italy
facility: ospedale regionale Miulli
state: Bari
Study officials:
References:
Clinical trial NCT01463878: Enteral Nutrition and Glycemic Variability Neurological Intensive Care Unit Study
Official title: Enteral Nutrition and Glycemic Variability NICU Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Subarachnoid Hemorrhage
Intracranial Hemorrhage
Ischemic Strokes
Subdural Hematoma
Keywords: glycemic control
glycemic variability
mean blood glucose level
Lead sponsor: Eastern Virginia Medical School
Sponsor class: OTHER
First posted: 2011-11-02
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary Objective:

To determine the effects of a diabetes specific enteral formula compared to a standard formula supplemented with protein (isocaloric and isonitrogenous) on the mean blood glucose and glycemic variability in a homogenous group of critically ill patients in a neurological ICU. Blood glucose will be recorded every minute using a continuous blood glucose monitor. The primary end points will be the difference between the mean blood glucose levels and the glucose variability between the control and intervention groups for the time period that the patient is in the ICU and receiving tube feeds and for up to a maximum of 14 days.

Secondary Objectives:

To determine the effects of the diabetes specific versus standard tube feeds on the change in muscle thickness and volume measured by 2-dimensional ultrasound imaging during the patients ICU stay.


Eligibility criteria: Inclusion Criteria:

* Patients aged between 18 and 89 years old
* Patients with critical illness including ischemic or hemorrhagic stroke, epidural/subdural bleeds and subarachnoid hemorrhage
* Patients who are expected to stay in the ICU for at least 5 days
* Hyperglycemia is not an inclusion criteria

Exclusion Criteria:

* Patients who have received or will be treated with systemic corticosteroids.
* Patients who will be receiving high doses of propofol (\>40 cc/hr)
* Patients with type 1 Diabetes
* Patients with sepsis or acute trauma
* Patients with an expected stay in the ICU of less than 4 days
* Patients who are unable to receive enteral nutrition or who have medical conditions precluding nutrition by the enteral route including allergies to formula components
* Pregnant and lactating patients
* Patients with prior history of gastroparesis
* Patients with acute kidney failure (creatinine \> 2.5mg/dl)
* Patients with acute liver failure (bilirubin \> 2.0 mg/dl)

Primary outcomes:
measure: Glycemic Variability
timeFrame: Entire ICU stay. Up to 14 days in the ICU (average about 7 days)
Secondary outcomes:
measure: Quadriceps Muscle Volume
timeFrame: First versus last measurment in ICU. Up to 14 days (average 7 days)
Other outcomes:
Locations:
city: Norfolk
country: United States
facility: Sentara Norfolk General Hospital
state: Virginia
Study officials:
affiliation: EVMS
name: Paul e Marik, MD
role: PRINCIPAL_INVESTIGATOR
References: